Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Pharm Dev Technol. 2013 Sep-Oct;18(5):1159-68. doi: 10.3109/10837450.2011.614251. Epub 2011 Sep 29.
The present study describes the design and characterization of nanostructured lipid carriers (NLCs) for controlled delivery of methotrexate (MTX). A series of NLCs with or without MTX were prepared using different ratios of liquid-lipid to solid-lipid and type and concentration of surfactants. The effect of different formulation parameters on the physical properties of NLCs, entrapment efficiency of MTX and in vitro drug release was evaluated. In addition, the in vitro delivery and cytotoxicity of MTX-loaded NLCs against human prostate cancer DU-145 cells and ovarian human cancer A2780 cells were investigated. Drug loading capacity, particle size and surface charge of the prepared NLCs and the in vitro MTX release were affected by the formulation parameters. In vitro growth inhibition assay using DU-145 and A2780 cancer cell lines showed that drug-free NLCs maintained cell viability while MTX-loaded NLCs inhibited the growth of both cell lines. In addition, MTX-loaded NLCs showed superior inhibitory effect on cell growth over the free drug especially in A2780 cell lines and a higher cytotoxic effect on DU-145 at higher drug concentration. The results of the current study warrant further exploration for the use NLCs as a controlled delivery system for chemotherapeutic agents.
本研究描述了载有甲氨蝶呤(MTX)的纳米结构脂质载体(NLC)的设计和特性。使用不同比例的液体脂质和固体脂质以及类型和浓度的表面活性剂制备了一系列载有或未载 MTX 的 NLC。评估了不同制剂参数对 NLC 的物理性质、MTX 包封效率和体外药物释放的影响。此外,还研究了载有 MTX 的 NLC 对人前列腺癌 DU-145 细胞和卵巢人癌细胞 A2780 细胞的体外递药和细胞毒性。载药 NLC 的载药能力、粒径和表面电荷以及体外 MTX 释放受到制剂参数的影响。使用 DU-145 和 A2780 癌细胞系进行的体外生长抑制测定表明,无载药 NLC 保持细胞活力,而载 MTX 的 NLC 抑制两种细胞系的生长。此外,载 MTX 的 NLC 对细胞生长的抑制作用优于游离药物,特别是在 A2780 细胞系中,在较高药物浓度下对 DU-145 具有更高的细胞毒性作用。本研究的结果证明了 NLC 作为化疗药物控释系统的进一步探索是合理的。